- Home
- Companies
- Celularity Inc.
- Products
- Celularity - Model CYNK-001 - ...
Celularity - Model CYNK-001 - Placental-derived Natural Killer (PNK) Cells
CYNK-001 is the only cryopreserved, allogeneic, off-the-shelf, natural killer (NK) cell therapy being developed from placental hematopoietic stem cells as a potential treatment option for various hematologic cancers, solid tumors, and infectious disease. NK cells are a unique class of immune cells, innately capable of targeting cancer cells and interacting with adaptive immunity.
CYNK-001 demonstrates a range of biological activities expected of NK cells, including expression of perforin and granzyme B, cytolytic activity against hematological tumors and solid tumor cell lines, and secretion of immunomodulatory cytokines such as IFN-γ in the presence of tumor cells. CYNK-001 cells express NKG2D and CD94, as well as NK activating receptors DNAM1, NKp30, NKp46, and NKp44.
We are investigating CYNK-001 in the clinic as a treatment for multiple cancer indications—multiple myeloma (MM), acute myeloid lymphoma (AML), and glioblastoma multiforme (GBM)—as well as for the emerging infectious disease, COVID-19.
Preclinical studies show that CYNK-001 displays cell killing activity against MM cells, AML cells, GBM cells, and SARS-CoV-2-infected cells in vitro. We are investigating CYNK-001 in vivo and expect it to work by augmenting the body’s natural immune response.